Pfizer Inc. (PFE) Shares Sold by AMP Capital Investors Ltd

AMP Capital Investors Ltd trimmed its position in Pfizer Inc. (NYSE:PFE) by 3.0% in the 3rd quarter, Holdings Channel reports. The firm owned 2,193,895 shares of the biopharmaceutical company’s stock after selling 67,786 shares during the quarter. AMP Capital Investors Ltd’s holdings in Pfizer were worth $78,322,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently made changes to their positions in PFE. Janus Henderson Group PLC raised its position in Pfizer by 243.5% during the second quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock valued at $442,574,000 after acquiring an additional 9,339,749 shares in the last quarter. Vanguard Group Inc. raised its position in Pfizer by 2.3% during the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after acquiring an additional 9,239,499 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Pfizer during the second quarter valued at approximately $268,389,000. Canada Pension Plan Investment Board raised its position in Pfizer by 249.6% during the second quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock valued at $359,871,000 after acquiring an additional 7,649,416 shares in the last quarter. Finally, Stifel Financial Corp raised its position in Pfizer by 5,413.5% during the third quarter. Stifel Financial Corp now owns 7,360,192 shares of the biopharmaceutical company’s stock valued at $262,515,000 after acquiring an additional 7,226,697 shares in the last quarter. Hedge funds and other institutional investors own 70.12% of the company’s stock.

Shares of Pfizer Inc. (NYSE:PFE) opened at $35.74 on Friday. The company has a market capitalization of $213,040.00, a P/E ratio of 10.15, a PEG ratio of 2.03 and a beta of 0.94. Pfizer Inc. has a 12-month low of $31.67 and a 12-month high of $39.43. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.06. The business had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The business’s revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.47 earnings per share. sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be paid a $0.34 dividend. The ex-dividend date is Thursday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.81%. Pfizer’s payout ratio is currently 38.64%.

Pfizer announced that its Board of Directors has initiated a share buyback program on Monday, December 18th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its stock is undervalued.

Several research analysts recently weighed in on PFE shares. BMO Capital Markets set a $39.00 price target on Pfizer and gave the company a “buy” rating in a research report on Tuesday, October 31st. JPMorgan Chase & Co. set a $39.00 price target on Pfizer and gave the company a “buy” rating in a research report on Wednesday, November 1st. UBS Group set a $38.00 price target on Pfizer and gave the company a “buy” rating in a research report on Wednesday, November 1st. Deutsche Bank set a $38.00 price target on Pfizer and gave the company a “buy” rating in a research report on Wednesday, December 6th. Finally, Vetr upgraded Pfizer from a “hold” rating to a “buy” rating and set a $38.82 price target for the company in a research report on Thursday, November 23rd. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $39.45.

In other news, insider Alexander R. Mackenzie sold 6,750 shares of Pfizer stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the sale, the insider now directly owns 103,458 shares of the company’s stock, valued at $3,827,946. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Rady A. Johnson sold 8,000 shares of Pfizer stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the sale, the executive vice president now directly owns 46,963 shares in the company, valued at $1,740,918.41. The disclosure for this sale can be found here. Insiders own 0.06% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://weekherald.com/2018/02/23/pfizer-inc-pfe-shares-sold-by-amp-capital-investors-ltd.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply